APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Oral Anticoagulants (DOACs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Direct Oral Anticoagulants (DOACs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025195 pages

Choose your research edition.

Industry ResearchDirect Oral Anticoagulants (DOACs) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Oral Anticoagulants (DOACs) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Direct Oral Anticoagulants (DOACs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Direct Oral Anticoagulants (DOACs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Direct Oral Anticoagulants (DOACs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Oral Anticoagulants (DOACs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Oral Anticoagulants (DOACs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Direct Oral Anticoagulants (DOACs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Direct Oral Anticoagulants (DOACs) Segment by Company

Accord Healthcare

Apotex

Boehringer Ingelheim

Bristol Myers Squibb

Daiichi Sankyo

GlaxoSmithKline

Janssen Pharmaceuticals

Teva Pharmaceutical

Viatris

Bayer

Pfizer

Mylan

Sandoz

Direct Oral Anticoagulants (DOACs) Segment by Type

Oral Factor Xa Inhibitors

Direct Thrombin Inhibitors (DTIs)

Direct Oral Anticoagulants (DOACs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Direct Oral Anticoagulants (DOACs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Oral Anticoagulants (DOACs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Direct Oral Anticoagulants (DOACs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Direct Oral Anticoagulants (DOACs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Direct Oral Anticoagulants (DOACs) Industry Trends Table 2. Direct Oral Anticoagulants (DOACs) Industry Drivers Table 3. Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges Table 4. Direct Oral Anticoagulants (DOACs) Industry Restraints Table 5. Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers Table 9. Global Direct Oral Anticoagulants (DOACs) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Direct Oral Anticoagulants (DOACs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Direct Oral Anticoagulants (DOACs) Manufacturers, Product Type & Application Table 13. Global Direct Oral Anticoagulants (DOACs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Direct Oral Anticoagulants (DOACs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Factor Xa Inhibitors Table 17. Major Manufacturers of Direct Thrombin Inhibitors (DTIs) Table 18. Global Direct Oral Anticoagulants (DOACs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 20. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 21. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026) Table 22. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2027-2032) Table 23. Global Direct Oral Anticoagulants (DOACs) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (K Units) Table 25. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (K Units) Table 26. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026) Table 27. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Pulmonary Embolism Table 29. Major Manufacturers of Deep Vein Thrombosis Table 30. Major Manufacturers of Atrial Fibrillation Table 31. Major Manufacturers of Other Table 32. Global Direct Oral Anticoagulants (DOACs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 34. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 35. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026) Table 36. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2027-2032) Table 37. Global Direct Oral Anticoagulants (DOACs) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (K Units) Table 39. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (K Units) Table 40. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2026) Table 41. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2027-2032) Table 42. Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units) Table 44. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2026) Table 45. Global Direct Oral Anticoagulants (DOACs) Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Direct Oral Anticoagulants (DOACs) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 49. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 50. Europe Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 52. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 59. Global Direct Oral Anticoagulants (DOACs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2026) Table 63. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2027-2032) Table 64. Accord Healthcare Company Information Table 65. Accord Healthcare Business Overview Table 66. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio Table 68. Accord Healthcare Recent Development Table 69. Apotex Company Information Table 70. Apotex Business Overview Table 71. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio Table 73. Apotex Recent Development Table 74. Boehringer Ingelheim Company Information Table 75. Boehringer Ingelheim Business Overview Table 76. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio Table 78. Boehringer Ingelheim Recent Development Table 79. Bristol Myers Squibb Company Information Table 80. Bristol Myers Squibb Business Overview Table 81. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio Table 83. Bristol Myers Squibb Recent Development Table 84. Daiichi Sankyo Company Information Table 85. Daiichi Sankyo Business Overview Table 86. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio Table 88. Daiichi Sankyo Recent Development Table 89. GlaxoSmithKline Company Information Table 90. GlaxoSmithKline Business Overview Table 91. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio Table 93. GlaxoSmithKline Recent Development Table 94. Janssen Pharmaceuticals Company Information Table 95. Janssen Pharmaceuticals Business Overview Table 96. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio Table 98. Janssen Pharmaceuticals Recent Development Table 99. Teva Pharmaceutical Company Information Table 100. Teva Pharmaceutical Business Overview Table 101. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio Table 103. Teva Pharmaceutical Recent Development Table 104. Viatris Company Information Table 105. Viatris Business Overview Table 106. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio Table 108. Viatris Recent Development Table 109. Bayer Company Information Table 110. Bayer Business Overview Table 111. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 113. Bayer Recent Development Table 114. Pfizer Company Information Table 115. Pfizer Business Overview Table 116. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 118. Pfizer Recent Development Table 119. Mylan Company Information Table 120. Mylan Business Overview Table 121. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio Table 123. Mylan Recent Development Table 124. Sandoz Company Information Table 125. Sandoz Business Overview Table 126. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio Table 128. Sandoz Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Direct Oral Anticoagulants (DOACs) Distributors List Table 132. Direct Oral Anticoagulants (DOACs) Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Direct Oral Anticoagulants (DOACs) Product Image Figure 2. Global Direct Oral Anticoagulants (DOACs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Oral Anticoagulants (DOACs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Oral Anticoagulants (DOACs) Sales (2021-2032) & (K Units) Figure 5. Global Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Factor Xa Inhibitors Image Figure 9. Direct Thrombin Inhibitors (DTIs) Image Figure 10. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Direct Oral Anticoagulants (DOACs) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2032) Figure 13. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2032) Figure 16. Pulmonary Embolism Image Figure 17. Deep Vein Thrombosis Image Figure 18. Atrial Fibrillation Image Figure 19. Other Image Figure 20. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Direct Oral Anticoagulants (DOACs) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2032) Figure 23. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2032) Figure 26. North America Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2032) Figure 28. U.S. Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2032) Figure 33. Germany Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2032) Figure 40. China Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2032) Figure 48. Brazil Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Direct Oral Anticoagulants (DOACs) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Direct Oral Anticoagulants (DOACs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Figure 59. North America Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Direct Oral Anticoagulants (DOACs) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Direct Oral Anticoagulants (DOACs) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical
  • Viatris
  • Bayer
  • Pfizer
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Direct Oral Anticoagulants (DOACs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Direct Oral Anticoagulants (DOACs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Direct Oral Anticoagulants (DOACs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Direct Oral Anticoagulants (DOACs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Direct Oral Anticoagulants (DOACs) Market Dynamics
  1. 2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
  2. 2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
  3. 2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
  4. 2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
3 Direct Oral Anticoagulants (DOACs) Market by Manufacturers
  1. 3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Direct Oral Anticoagulants (DOACs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Direct Oral Anticoagulants (DOACs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Direct Oral Anticoagulants (DOACs) Manufacturers, Product Type & Application
  7. 3.7 Global Direct Oral Anticoagulants (DOACs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Direct Oral Anticoagulants (DOACs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3
4 Direct Oral Anticoagulants (DOACs) Market by Type
  1. 4.1 Direct Oral Anticoagulants (DOACs) Type Introduction
  2. 4.1.1 Oral Factor Xa Inhibitors
  3. 4.1.2 Direct Thrombin Inhibitors (DTIs)
  4. 4.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type
  5. 4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  7. 4.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Type
  9. 4.3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  11. 4.3.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2032)
5 Direct Oral Anticoagulants (DOACs) Market by Application
  1. 5.1 Direct Oral Anticoagulants (DOACs) Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application
  7. 5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  9. 5.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2032)
  10. 5.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Application
  11. 5.3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  13. 5.3.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2032)
6 Global Direct Oral Anticoagulants (DOACs) Sales by Region
  1. 6.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2032)
  3. 6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026)
  4. 6.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Direct Oral Anticoagulants (DOACs) Revenue by Region
  1. 7.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region
  2. 7.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Direct Oral Anticoagulants (DOACs) Revenue (2021-2032)
  8. 7.2.2 North America Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Direct Oral Anticoagulants (DOACs) Revenue (2021-2032)
  11. 7.3.2 Europe Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol Myers Squibb
  20. 8.4.1 Bristol Myers Squibb Company Information
  21. 8.4.2 Bristol Myers Squibb Business Overview
  22. 8.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
  24. 8.4.5 Bristol Myers Squibb Recent Developments
  25. 8.5 Daiichi Sankyo
  26. 8.5.1 Daiichi Sankyo Company Information
  27. 8.5.2 Daiichi Sankyo Business Overview
  28. 8.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
  30. 8.5.5 Daiichi Sankyo Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Janssen Pharmaceuticals
  38. 8.7.1 Janssen Pharmaceuticals Company Information
  39. 8.7.2 Janssen Pharmaceuticals Business Overview
  40. 8.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
  42. 8.7.5 Janssen Pharmaceuticals Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Viatris
  50. 8.9.1 Viatris Company Information
  51. 8.9.2 Viatris Business Overview
  52. 8.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
  54. 8.9.5 Viatris Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Mylan
  68. 8.12.1 Mylan Company Information
  69. 8.12.2 Mylan Business Overview
  70. 8.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
  72. 8.12.5 Mylan Recent Developments
  73. 8.13 Sandoz
  74. 8.13.1 Sandoz Company Information
  75. 8.13.2 Sandoz Business Overview
  76. 8.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
  78. 8.13.5 Sandoz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
  2. 9.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Direct Oral Anticoagulants (DOACs) Production Mode & Process
  6. 9.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Direct Oral Anticoagulants (DOACs) Distributors
  9. 9.2.3 Direct Oral Anticoagulants (DOACs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst